Pharmacology and Therapeutics Advisory Committee (PTAC)

PTAC's role is to provide objective clinical advice to Pharmac.

On this page

Last updated:

6 December 2021: Membership updated to remove Sean Hanna.

About PTAC

PTAC provides objective clinical advice to help Pharmac make decisions about how to use its funds wisely. It provides and promotes critical appraisal of the strength and quality of evidence for funding applications. This is applied rigorously, systematically, and consistently across all clinical areas.

It's made up of senior health practitioners from a range of specialities, who also regularly work with patients and their families. This means they can bring an evidence-based perspective but also provide insight on how Pharmac’s decisions apply to real people in New Zealand.

The full details of PTAC’s remit can be found in its Terms of Reference. The Terms of Reference were updated in 2021 to include the potential to have a consumer member, and increase consumer perspectives, on PTAC. Te Tiriti and health equity expertise are also more strongly centred than previously.

Read the 2021 Terms of Reference

A recommendation from PTAC is not guarantee that Pharmac will fund the medicine. PTAC’s advice is a vital step in the process for considering all funding applications, but it is not the only consideration. Pharmac must look at the whole picture to ensure we are getting the best health outcomes for New Zealand.

We publish PTAC minutes on the website once they are agreed by the committee.

PTAC members

Jane Thomas (Chair) – Paediatric Anaesthesia and Pain Medicine Specialist
MBChB, FANZCA, FFPMANZCA
Marius Rademaker (Deputy Chair) – Dermatologist
BM (Soton), MRCP (UK), JCHMT Accreditation, DM, FRCP (Edin), FRACP
Brian Anderson – Anaesthesia & Intensive Care Medicine Specialist
MBChB, Dip Obst, FANZCA, FCICM, PhD
Rhiannon Braund – Clinical Pharmacist
PhD, BPharm, BSc (Biochemistry), FPS, FNZCP
Elizabeth Dennett – General Surgery - Colorectal
BMedSci, MBChB, GradDipMed, MMedSci, MAppMgt(Hlth), FRACS, FASCRS
Alan Fraser – Gastroenterologist
MBChB, MD, FRACP
Bruce King – Specialist Internal Medicine and Nephrology
MBChB, FRACP
Jennifer Martin – Clinical Pharmacologist
MBChB, MA(Oxon.), FRACP, PhD
Stephen Munn – Transplant Surgeon
MBChB, FRACS, FACS
Giles Newton-Howes – Psychiatrist
BA, BSc, MBChB, MRCPsych, PostDip BD, FRANZCP
Lisa Stamp – Internal Medicine and Rheumatology
MBChB, FRACP, PhD, PGCertStratLdrship
Tim Stokes – General Practitioner
MA, MBChB, MPH, PhD, FRCP, FRCGP, FRNZCGP
Matthew Strother – Medical Oncologist
MD (USA), FRACP
Simon Wynn Thomas – General Practitioner
BMedSci (UK), MRCP (UK), MRCGP (UK), DFFP, FRNZCGP

Read the announcement of the appointment of a new chair (November 2021)

PTAC members are appointed by the Director-General of Health, in consultation with the Pharmac Board. This process is guided by an appointment protocol [PDF, 72 KB].

Interested senior health practitioners can apply directly or are nominated by professional medical bodies, such as the Royal New Zealand College of General Practitioners and the Royal Australasian College of Physicians. Vacancies are posted on the Pharmac careers page(external link).

PTAC's part in the funding process

PTAC's role in considering funding applications is set out in Pharmac’s Operating Policies and Procedures. Pharmac will assess the initial funding application and notify the applicant whether:

it will be considered by PTAC
it will be considered by a PTAC subcommittee, or
further information is required before an assessment can be made.

If you are seeking funding for a specific patient with exceptional circumstances, you can submit a Named Patient Pharmaceutical Assessment (NPPA) application.

Deadlines for PTAC meetings

If Pharmac chooses to seek PTAC advice on a funding application, the application must have been received by the following dates to be available for consideration at one of PTAC’s four annual meetings.

Deadline for an application to be received by Pharmac, to be considered by PTAC:	PTAC’s meeting date:
16 August 2021	18 and 19 November 2021*
8 November 2021	17 and 18 February 2022
21 February 2022	19 and 20 May 2022
23 May 2022	18 and 19 August 2022
22 August 2022	17 and 18 November 2022

* Dates for this meeting were corrected on 15 September 2021. This correction has no impact on the application deadline and/or any applications received for this meeting. (Previous dates were 12 and 13 November).

November 2021 PTAC meeting

Applications reviewed at this PTAC meeting were:

Daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis
Lanthanum carbonate for CKD
Upadacitinib for atopic dermatitis
Elexacaftor/tezacaftor/ivacaftor for treatment of cystic fibrosis patients aged 6 years and older with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene